Sandoz international
Index Globenewswire
Sandoz Delivers Strong H1 2025 Results, with Accelerated Sales Growth in the Second Quarter
Jumat, 08 Agustus 2025 - 01:02:19 Wib Globenewswire
Sandoz Launches Pyzchiva® Autoinjector, First Commercially Available in Europe for Ustekinumab Biosimilars
Kamis, 22 Mei 2025 - 04:32:42 Wib Globenewswire
Sandoz Reports Q1 2025 Net Sales in Line with Company Expectations; Full-year Guidance Confirmed
Rabu, 30 April 2025 - 22:09:41 Wib Globenewswire
[Corrected] Sandoz Files Antitrust Litigation Against Amgen Regarding Patient Access to Etanercept Biosimilar in the US
Senin, 14 April 2025 - 21:30:00 Wib Globenewswire
Sandoz Files Antitrust Litigation Against Amgen Regarding Patient Access to Etanercept Biosimilar in the US
Senin, 14 April 2025 - 12:13:00 Wib Globenewswire
Sandoz Reports Strong FY 2024 Results and Q4 2024 Sales
Kamis, 06 Maret 2025 - 11:59:16 Wib Globenewswire
Sandoz Launches Biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, Offering New Treatment for Around 12 Million Patients[1-4]
Senin, 24 Februari 2025 - 13:30:00 Wib Globenewswire
Francisco Ballester to Retire; Peter Stenico Appointed President Region International
Senin, 03 Februari 2025 - 13:30:00 Wib Globenewswire
Sandoz to Confirm Strategic Roadmap and Highlight Pipeline Catalysts at 43rd Annual J.P. Morgan Healthcare Conference
Selasa, 14 Januari 2025 - 13:30:00 Wib Globenewswire
Sandoz Takes Further Steps to Resolve Legacy US Generic Drug Antitrust Class Action Litigation
Selasa, 17 Desember 2024 - 13:30:00 Wib Globenewswire
Sandoz Receives European Commission Approval for Afqlir® (aflibercept), Further Strengthening Leading Biosimilar Portfolio
Jumat, 15 November 2024 - 13:30:00 Wib Globenewswire
Sandoz Reports Third-quarter and Nine-month 2024 Sales
Rabu, 30 Oktober 2024 - 13:30:00 Wib Globenewswire
Sandoz Receives FDA Approval for Enzeevu™ (Aflibercept-abzv), Further Strengthening US Biosimilar Position
Senin, 12 Agustus 2024 - 12:30:00 Wib Globenewswire
Sandoz Reports Second-quarter Sales and Half-year 2024 Results
Kamis, 08 Agustus 2024 - 12:03:22 Wib Globenewswire
Sandoz Launches Biosimilar Pyzchiva® (ustekinumab) Across Europe, to Treat Chronic Inflammatory Diseases
Kamis, 25 Juli 2024 - 12:30:00 Wib Globenewswire
FDA Approves Biosimilar Pyzchiva® (ustekinumab-ttwe), to be Commercialized by Sandoz in US
Senin, 01 Juli 2024 - 22:07:55 Wib Globenewswire
Sandoz Receives European Commission Approval for Wyost® and Jubbonti®, the First and Only Biosimilars of Denosumab in Europe
Kamis, 23 Mei 2024 - 05:04:32 Wib Globenewswire
Shareholders Approve All Resolutions Proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Rabu, 01 Mei 2024 - 03:17:16 WibTerpopuler
Index
